A detailed history of Advisor Group Holdings, Inc. transactions in Cellectis S.A. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,080 shares of CLLS stock, worth $2,203. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,080
Previous 4,580 76.42%
Holding current value
$2,203
Previous $14,000 85.71%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$2.41 - $3.09 $8,435 - $10,815
-3,500 Reduced 76.42%
1,080 $2,000
Q4 2023

Feb 12, 2024

SELL
$0.97 - $3.55 $4,258 - $15,584
-4,390 Reduced 48.94%
4,580 $14,000
Q3 2023

Nov 13, 2023

BUY
$1.58 - $2.86 $5,695 - $10,310
3,605 Added 67.19%
8,970 $14,000
Q2 2023

Aug 10, 2023

SELL
$1.72 - $2.12 $1,453 - $1,791
-845 Reduced 13.61%
5,365 $10,000
Q1 2023

May 12, 2023

SELL
$1.83 - $3.84 $49 - $103
-27 Reduced 0.43%
6,210 $11,000
Q4 2022

Feb 10, 2023

SELL
$1.85 - $2.53 $307 - $419
-166 Reduced 2.59%
6,237 $13,000
Q3 2022

Nov 14, 2022

SELL
$2.42 - $4.08 $968 - $1,632
-400 Reduced 5.88%
6,403 $15,000
Q2 2022

Aug 10, 2022

SELL
$2.39 - $4.93 $207 - $428
-87 Reduced 1.26%
6,803 $19,000
Q1 2022

May 04, 2022

BUY
$3.45 - $8.77 $13,948 - $35,457
4,043 Added 142.01%
6,890 $32,000
Q3 2021

Nov 05, 2021

SELL
$11.94 - $16.09 $129,059 - $173,916
-10,809 Reduced 79.15%
2,847 $36,000
Q2 2021

Aug 02, 2021

SELL
$14.36 - $20.93 $102,659 - $149,628
-7,149 Reduced 34.36%
13,656 $212,000
Q1 2021

May 13, 2021

BUY
$18.19 - $33.25 $42,673 - $78,004
2,346 Added 12.71%
20,805 $421,000
Q4 2020

Feb 10, 2021

SELL
$15.87 - $31.64 $11,680 - $23,287
-736 Reduced 3.83%
18,459 $500,000
Q3 2020

Nov 12, 2020

SELL
$15.7 - $20.84 $12,277 - $16,296
-782 Reduced 3.91%
19,195 $356,000
Q2 2020

Aug 14, 2020

SELL
$8.21 - $21.02 $311 - $798
-38 Reduced 0.19%
19,977 $355,000
Q1 2020

May 18, 2020

BUY
$7.81 - $18.82 $156,317 - $376,682
20,015 New
20,015 $184,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $92.8M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.